semaglutide cardiovascular outcomes news 2025 october and by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Oral Semaglutide Reduces Cardiovascular Events

Long-Term Safety Data Long-term studies and clinical trials have provided valuable data on the safety of semaglutide: Cardiovascular Safety: Semaglutide has been shown to reduce the risk of major cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes and established cardiovascular disease

"Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis"

This may cause cloudiness, visible particles, clumping, foaming, gel formation, aggregation, or precipitation

Results for prostate cancer, however, have been contradictory, with numerous observational studies indicating an elevated risk for prostate cancer with larger calcium intakes

The analysis confirms that employers using Digbi Healths Precision Biology platform achieved actuarially guaranteed, hard-dollar reductions in medical claims, driven by lower pharmaceutical utilization and reduced inpatient and outpatient costs